Financial Reporting/Disclosure
| Reporting Status |
International Reporting: ASX - Australian Securities Exchange
|
| Audited Financials |
Audited |
| Latest Report |
Mar 31, 2017 Quarterly Report |
| CIK |
0001308380 |
| Fiscal Year End |
6/30 |
| OTC Marketplace |
OTCQX International |
Profile Data
| SIC - Industry Classification |
8731 - Commercial physical research |
| Incorporated In: |
Australia |
| Year of Inc. |
1997 |
| Employees |
40 a/o Jul 01, 2011 |
Company Officers/Contacts
| Dr. Jackie Fairley |
CEO, IR, Managing Director |
| Nigel Baade |
CFO, Secretary |
Company Directors
| Robert Thomas |
Chairman |
| Richard Hazleton |
Independent Director, Audit Committee Member, Compensation Committee Member, Nominating Committee Member |
| Zita Peach |
|
| Peter Turvey |
|
Service Providers
Accounting/Auditing Firm
Securities Counsel
Investor Relations Firm
Company History
- Sponsored for OTCQX by BNY Mellon on 3/26/2007.
- Formerly=Starpharma Pooled Development Ltd. until 4-04
Share Structure
|
Market Value1 |
$197,904,243 |
a/o Jun 22, 2017 |
|
Authorized Shares |
Unlimited |
a/o Dec 05, 2016 |
|
Outstanding Shares |
368,536,766 |
a/o Dec 05, 2016 |
|
-Restricted |
Not Available |
|
-Unrestricted |
Not Available |
|
Held at DTC |
Not Available |
|
Float |
Not Available |
|
Par Value |
No Par Value
|
Shareholders
| Shareholders of Record |
4,956 |
a/o Jul 31, 2016 |
Corporate Actions
|
Ex. Date |
Record Date |
Pay Date |
| |
| Dividends are not adjusted for stock splits |
Non US Stock Exchange Listing
| SPL - ASX - Australian Securities Exchange - Qualified |
1Market Value calculated only for respective security
Verified Company Profile
1/12/2017
